KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

GoodRx Holdings (GDRX) EBIAT (2019 - 2025)

GoodRx Holdings' EBIAT history spans 7 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, EBIAT fell 19.51% year-over-year to $5.4 million; the TTM value through Dec 2025 reached $30.4 million, up 85.72%, while the annual FY2025 figure was $30.4 million, 85.72% up from the prior year.
  • EBIAT for Q4 2025 was $5.4 million at GoodRx Holdings, up from $1.1 million in the prior quarter.
  • Across five years, EBIAT topped out at $58.8 million in Q2 2023 and bottomed at -$41.7 million in Q3 2022.
  • The 5-year median for EBIAT is $1.4 million (2021), against an average of -$1.0 million.
  • The largest YoY upside for EBIAT was 4254.49% in 2023 against a maximum downside of 1211.82% in 2023.
  • A 5-year view of EBIAT shows it stood at -$39.9 million in 2021, then soared by 95.06% to -$2.0 million in 2022, then crashed by 1211.82% to -$25.9 million in 2023, then skyrocketed by 126.05% to $6.7 million in 2024, then fell by 19.51% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's EBIAT are $5.4 million (Q4 2025), $1.1 million (Q3 2025), and $12.8 million (Q2 2025).